An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.
With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
Hopes that biologic drugs for rheumatoid arthritis (RA) would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.
In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.
Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.
Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.
The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder.
A study of men with gout from the US Veteran’s Health Administration (VHA) shows that excess mortality in gout could be attributed to comorbidities.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
